Die Studie hat die gesundheitliche Entwicklung von 900 Erwachsenen über 20 Jahre verfolgt. Dabei wurde ermittelt, dass NSAIDs wie Ibuprofen und Naproxen auf der einen Seite das Risiko für Mundkrebs bei Rauchern halbieren, auf der anderen Seite aber das Risiko für Tod durch Herzinfarkt verdoppeln. Ausnahme bei den NSAIDs bzgl. Herzinfarktrisiko bleibt Aspirin.
Use of mon-COX-2-specific NSAIDs halves odds for oral cancer: Doubles cardiovascular death risk
Norwegian Radium Hospital, NewYork-Presbyterian/Weill Cornell, M. D. Anderson findings support recent move by FDA to place 'black box' warning on painkillers such As Ibuprofen and Naproxen
NEW YORK (October 6, 2005) - An analysis of 20 years of data on the health of over 900 adults has found that long-term use of traditional nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen, cuts the risk for oral cancer in smokers by half.
However, use of these pain relievers (with the exception of aspirin) for 6 months or more also doubled users' risks for cardiovascular death, according to collaborative research published online Oct. 7 by The Lancet.
The study was conducted by researchers at the Norwegian Radium Hospital and The National Hospital in Oslo; University of Science and Technology, Trondheim, Norway; NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City; The University of Texas M. D. Anderson Cancer Center in Houston; and the University of Helsinki.
"Our findings highlight how a commonly used drug can have a benefit from the standpoint of cancer prevention but can also have side effects - in this case, an increased risk for cardiovascular death," said co-researcher Dr. Andrew Dannenberg, the Henry R. Erle, M.D., Professor of Medicine at Weill Medical College of Cornell University and Director of Cancer Prevention at NewYork-Presbyterian/Weill Cornell.
The findings "also support moves by the U.S. Food and Drug Administration, which recently mandated special 'black box' warning labels on all NSAID pain relievers except aspirin, warning consumers of potential cardiovascular side effects linked to long-term use," added lead researcher Dr. Jon Sudbø, a senior consultant in the Department of Medical Oncology and Radiotherapy at Norwegian Radium Hospital.
Weitere Infos finden sich hier.